Author:
Takaoka Naoko,Tsujita Kenichi,Kaikita Koichi,Hokimoto Seiji,Yamanaga Kenshi,Komura Naohiro,Chitose Tadasuke,Ono Takamichi,Mizobe Michio,Horio Eiji,Sato Koji,Nakayama Naoki,Saito Michiyo,Iwashita Satomi,Kojima Sunao,Tayama Shinji,Sugiyama Seigo,Nakamura Sunao,Ogawa Hisao
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine
Reference41 articles.
1. Imamura T, Doi Y, Arima H, Yonemoto K, Hata J, Kubo M, Tanizaki Y, Ibayashi S, Iida M, Kiyohara Y (2009) LDL cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population: the Hisayama study. Stroke 40:382–388
2. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278
3. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P (2008) The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 102:1K–34K
4. Ogita M, Miyauchi K, Miyazaki T, Naito R, Konishi H, Tsuboi S, Dohi T, Kasai T, Yokoyama T, Okazaki S, Kurata T, Daida H (2013) Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol. Heart Vessels. doi: 10.1007/s00380-013-0330-5
5. Falk E, Shah PK, Fuster V (1995) Coronary plaque disruption. Circulation 92:657–671